Last reviewed · How we verify
Axitinib (AG-013736) (axitinib-ag-013736)
Axitinib is a marketed drug by Pfizer Inc. for advanced renal cell carcinoma (RCC). It works by inhibiting vascular endothelial growth factor receptors (VEGFRs). Axitinib is used as a first-line treatment and after failure of prior therapy. It has a significant commercial presence with $63.6B in revenue. The drug's mechanism and clinical differentiation make it a key player in the RCC treatment landscape. Axitinib's pipeline developments are not publicly disclosed. Its commercial significance is evident in its revenue and market presence.
At a glance
| Generic name | axitinib-ag-013736 |
|---|---|
| Sponsor | Pfizer |
| Drug class | tyrosine kinase inhibitor |
| Target | vascular endothelial growth factor receptors (VEGFRs) |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Advanced renal cell carcinoma (RCC) after failure of prior therapy
- Advanced renal cell carcinoma (RCC) as a first-line treatment
Common side effects
Drug interactions
- Warfarin
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)
- CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin)
- Strong CYP3A4 inhibitors (e.g., atazanavir, indinavir, nelfinavir, ritonavir)
- CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin)
- CYP1A2 inducers (e.g., smoking, phenobarbital)
- CYP2C8 inhibitors (e.g., gemfibrozil)
- CYP2C8 inducers (e.g., rifampin)
- CYP2C19 inhibitors (e.g., omeprazole, esomeprazole)
- CYP2C19 inducers (e.g., rifampin)
- CYP2D6 inhibitors (e.g., paroxetine, fluoxetine)
- CYP2D6 inducers (e.g., rifampin)
Key clinical trials
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (PHASE2)
- Drug Screening Using Novel IMD in Renal Cell Carcinoma (PHASE1)
- Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy (PHASE3)
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial (PHASE1)
- An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Axitinib (AG-013736) CI brief — competitive landscape report
- Axitinib (AG-013736) updates RSS · CI watch RSS
- Pfizer portfolio CI